Precise drug and dose according to the patient’s pharmacogenetic profile
Drugs are often prescribed without knowing a patient’s genetic profile. As a result, the patient may have to undergo several treatment trials before an effective treatment is found. On the other hand, some patients experience severe adverse effects that could have been avoided if the patient’s genetic profile had been known at the time of prescription. In a large, randomised study using pharmacogenetically guided prescription, the risk of adverse drug reactions reduced by 30% (1). Sometimes genetic testing is even a prerequisite for the use of a drug.
30%
“Pharmacogenetic intervention reduced the risk of adverse drug reaction.”
Clinical solution
Pgxbase serves as a resource for tailoring drug therapies to the unique genetic profile of a patient. Precise drug treatment can be extended from specialists in pharmacogenetics to all healthcare professionals involved in prescribing or dispensing drugs. Pgxbase enables healthcare providers to prescribe the right drug at the right dose for each patient, with reduced risk of adverse effects or lack of efficacy.
Key characteristics
of Pgxbase
- Inclusion of pharmacogenetically sensitive drugs. Classification of whether a genetic test is required for the use of a drug according to the Summary of Product Characteristics (SPC)
- Drug dosing based on patient phenotype for drug metabolising enzymes or drug transporters
- Recommendation of drug use in the presence of gene variants associated with toxicity
- Paediatric recommendations
- Information on adverse effects if genetic variants are not taken into consideration
- Alternative drug options
- Gene information with literature references
- Phenoconversion addressed by combining Pgxbase and Inxbase
Classification methodology
Classification and recommendations in Pgxbase
Classifications and recommendations are presented using a system of traffic lights and letters ranging from A to D, according to the need for clinical action.
| D | Significantly increased risk for altered drug exposure or toxicity – use should be avoided |
| C | Clinically relevant effect on drug exposure or toxicity – action recommended |
| B | Clinical outcome is uncertain and/or may vary |
| A | Minor or no clinical relevance |
The evidence is graded according to the following scale:
| 0 | Evidence is extrapolated from studies on similar type of drugs |
| 1 | Evidence is from anecdotal case reports and insufficient to draw clinical conclusions |
| 2 | Evidence is from well-defined case series OR clinical or epidemiological studies suffering from design issues |
| 3 | Evidence is from randomised controlled studies on healthy individuals or retrospective epidemiological studies |
| 4 | Evidence is from good quality randomised controlled trials or epidemiological studies on adequate patient populations |
Languages and local drug registries
Medbase content is available in English and more than ten additional languages. To further improve local usability, we accommodate national, local and customer-specific drug product registries, allowing access to information using local drug product names and IDs.
Integration with local electronic health record (EHR) systems is straightforward, enabling smooth and efficient use of regularly updated Medbase drug information across various countries.
Latest information from trusted sources
All information is based on scientific evidence. We refer to published, peer-reviewed research articles from PubMed, a reliable source of biomedical and life sciences literature, as well as regulatory authority approved documents, such as the Summaries of Product Characteristics (SPC) of drugs. In addition, published recommendations by pharmacogenetic consortium/working groups such as CPIC (The Clinical Pharmacogenetics Implementation Consortium) and DPWG (Dutch Pharmacogenetics Working Group) have been reviewed.
Information in the Medbase Knowledgebase is continuously updated to ensure the inclusion of the latest information.
Supporting informed decisions for safe drug use
Enhanced patient safety
Holistic approach to patient’s pharmacotherapy enabling individualised drug treatment.
100% Evidence-based
Fully referenced information with transparency to original sources: documents approved by regulatory authorities and peer-reviewed literature.
Clinical relevance
We provide comprehensive and concise information for safe use of drugs, accessible from one single source.
Digitalised doctor consultation
Designed to support busy clinical practice for safe use of drugs. All information is created and validated by physicians specialised in clinical pharmacology.
Newsroom
Discover our latest updates & customer references
Genetic variability affects outcomes of drug therapy
- Interview
- PROF. MIKKO NIEMI
“Our product development is foresighted”
- Our People
- CPO MARKUS JANSÉN
Vaaka Partners to invest in Medbase
- Interview
- Swen JJ, van der Wouden CH, Manson LE, et al. A 12-gene pharmacogenetic panel to prevent adverse drug reactions: an open-label, multicentre, controlled, cluster-randomised crossover implementation study. Lancet. 2023 Feb 4;401(10374):347-356. doi: 10.1016/S0140-6736(22)01841-4. Erratum in: Lancet. 2023 Aug 26;402(10403):692. doi: 10.1016/S0140-6736(23)01742-7. PMID: 36739136